Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Gains from Investment Securities (2022 - 2025)

Taysha Gene Therapies' Gains from Investment Securities history spans 4 years, with the latest figure at -$302000.0 for Q3 2025.

  • For Q3 2025, Gains from Investment Securities fell 544.12% year-over-year to -$302000.0; the TTM value through Sep 2025 reached -$214000.0, down 100.62%, while the annual FY2024 figure was $3.7 million, 144.03% up from the prior year.
  • Gains from Investment Securities for Q3 2025 was -$302000.0 at Taysha Gene Therapies, down from $178000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $34.5 million in Q4 2023 and bottomed at -$338000.0 in Q2 2024.
  • The 4-year median for Gains from Investment Securities is $68000.0 (2024), against an average of $4.2 million.
  • The largest annual shift saw Gains from Investment Securities surged 8592.7% in 2023 before it crashed 544.12% in 2025.
  • A 4-year view of Gains from Investment Securities shows it stood at $397000.0 in 2022, then soared by 8592.7% to $34.5 million in 2023, then tumbled by 100.24% to -$83000.0 in 2024, then plummeted by 263.86% to -$302000.0 in 2025.
  • Per Business Quant, the three most recent readings for TSHA's Gains from Investment Securities are -$302000.0 (Q3 2025), $178000.0 (Q2 2025), and -$7000.0 (Q1 2025).